EMA Committee Warns Ibuprofen Can Seriously Exacerbate Infections
Executive Summary
EMA's Pharmacovigilance Risk Assessment Committee wants ibuprofen and ketoprofen products to carry new warnings related to the risk of exacerbating serious infections.
You may also be interested in...
EU Warns Flurbiprofen Can Potentially Mask Infection Symptoms
Popular OTC sore throat treatment flurbiprofen can possibly mask the symptoms of infection and lead to treatment delays, according to EU medicines regulators. Products sold in the EU containing flurbiprofen will soon be required to carry information warning patients and healthcare professionals about this risk.
Next Generation OTC Painkillers And Cough Syrup On Cards For German Switch Committee
Rx-to-OTC switches of the painkillers dexibuprofen and single-pill combinations of ibuprofen and paracetamol as well as the cough medicine levodropropizine, all for oral use, will be considered at the next German Expert Committee for Prescription meeting on 13 July.
EU Regulatory Round-Up: COVID-19 Continuity, Ibuprofen Warnings, Nitrosamines, Ranitidine
The latest EU OTC regulatory news: the EMA with EC and NCAs publish COVID-19 Business Continuity Plan; the CMDh decides to implement the PRAC's recommendations for ibuprofen and ketoprofen; the EMA and HMAs learn lessons from N-nitrosamine impurities in sartans; and the CHMP revisits its opinion on ranitidine following a request by a manufacturer.